March 3, 2020 07:04 AM EST

In record-setting settlement, Novartis’ Sandoz unit admits guilt in conspiracy to fix prices

Jason Mast

Editor

Becoming the largest drugmaker to plead guilty in a wide-ranging Justice Department generics probe, Novartis admitted to price-fixing charges and agreed to a record-setting settlement …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

In record-setting settlement, Novartis’ Sandoz unit admits guilt in conspiracy to fix prices

Jason Mast

Editor

Sign up to read this article for free.

FDA widens Sarepta’s Duchenne gene therapy label to older boys in significant expansion of use

Scientists just discovered a new genetic clue for delaying Alzheimer’s disease. It’s already inspiring drug ...

Gilead's twice-a-year injection fully prevented HIV in Phase 3 study with cisgender women

Silence’s siRNA candidate for cardiovascular disease continues to deliver in Phase 2 trial

Takeda budgets $230M for plasma therapy facility expansion in California

FDA to pharma companies: Using CRO Synapse's studies 'unacceptable'

In record-set­ting set­tle­ment, No­var­tis’ San­doz unit ad­mits guilt in con­spir­a­cy to fix prices

Jason Mast

Editor

Sign up to read this article for free.

more like this

FDA widens Sarep­ta’s Duchenne gene ther­a­py la­bel to old­er boys in sig­nif­i­cant ex­pan­sion of use

Sci­en­tists just dis­cov­ered a new ge­net­ic clue for de­lay­ing Alzheimer’s dis­ease. It’s al­ready in­spir­ing drug ...

Gilead­'s twice-a-year in­jec­tion ful­ly pre­vent­ed HIV in Phase 3 study with cis­gen­der women

Si­lence’s siR­NA can­di­date for car­dio­vas­cu­lar dis­ease con­tin­ues to de­liv­er in Phase 2 tri­al

Take­da bud­gets $230M for plas­ma ther­a­py fa­cil­i­ty ex­pan­sion in Cal­i­for­nia

FDA to phar­ma com­pa­nies: Us­ing CRO Synapse's stud­ies 'u­nac­cept­able'

In record-setting settlement, Novartis’ Sandoz unit admits guilt in conspiracy to fix prices

FDA widens Sarepta’s Duchenne gene therapy label to older boys in significant expansion of use

Scientists just discovered a new genetic clue for delaying Alzheimer’s disease. It’s already inspiring drug ...

Gilead's twice-a-year injection fully prevented HIV in Phase 3 study with cisgender women

Silence’s siRNA candidate for cardiovascular disease continues to deliver in Phase 2 trial

Takeda budgets $230M for plasma therapy facility expansion in California

FDA to pharma companies: Using CRO Synapse's studies 'unacceptable'